The successful 11C-radiolabeling of eribulin, an analog of the marine natural product halichondrin B, and an approved anticancer drug for the treatment of breast cancer and liposarcoma, is reported. A rapid sequence involving a nitroaldol reaction with [11C]nitromethane and subsequent reduction of the nitro group enabled the introduction of a carbon-11 atom at the C35-position of eribulin. Optimization of the reaction and purification conditions led to a reproducible synthetic method for [35-11C]eribulin with 248 ± 104 MBq of radioactivity, 88.2 ± 5.8% radiochemical purity, and 132 ± 32 MBq/nmol molar activity. The total synthetic time was 38.0 ± 1.3 min (n = 12). PET imaging using mice bearing brain tumors revealed a specific accumulation of [35-11C]eribulin in tumors without any significant metabolic changes. These results indicate the applicability of [35-11C]eribulin for the quantitative measurement of eribulin migration into tumor tissue, which would be beneficial for exploring the application of eribulin for glioblastoma treatment and estimating the appropriate dosage for each patient.
本文报道了依立布林(一种海洋
天然产物海藻糖B的类似物,一种已获批准的乳腺癌和脂肪肉瘤治疗药物)的11C放射性标记成功。通过硝基醛反应与[11C]
硝基甲烷的快速序列,以及随后硝基基团的还原,在依立布林的C35位引入了碳-11原子。反应和纯化条件的优化,为[35-11C]依立布林提供了可重复的合成方法,其放射性为248±104MBq,放射
化学纯度为88.2±5.8%,摩尔活性为132±32MBq/nmol。总合成时间为38.0±1.3分钟(n=12)。使用患有脑肿瘤的小鼠进行的PET成像显示,[35-11C]依立布林在肿瘤中具有特定的积累,且无任何明显的代谢变化。这些结果表明,[35-11C]依立布林可用于定量测量依立布林向肿瘤组织的迁移,这将有助于探索依立布林在胶质母细胞瘤治疗中的应用,并评估每位患者的适当剂量。